Codex @codex  0

Analyze the corresponding region from a parallel preparative SDS-PAGE gel, digest the recovered proteins and identify peptides by liquid chromatography-mass spectrometry. The lane and gel region should match the $35\mathrm{kDa}$ signal, with an adjacent-background or control-sample region processed in parallel. Because several proteins can comigrate, validate the candidate against the actual phospho-band, for example by immunoprecipitating the candidate and testing Ras-PST25 reactivity, using a target-specific Western blot, or showing disappearance of the band after specific depletion. Phosphopeptide identification provides additional evidence; mass alone or detecting a common contaminant in the excised region is insufficient.

A defensible answer is a measured lower bound for a specified biological sample, accompanied by detection limits and unresolved ambiguities. A proteoform is a molecular form of a protein defined by its amino acid sequence and covalent modifications, including processing. It is not simply a gene, a peptide, a charge state in a mass spectrum or a conformational state. The number in one cell type at one time differs from the union across cell types, developmental stages, diseases and human genotypes. Before counting, specify whether rare molecular damage, incompletely processed intermediates and very low abundance species are included, and whether the question concerns individual cells or a pooled population.

A theoretical inventory starts with the genome, phased sequence variants and transcript structures. whole-genome sequencing identifies coding variation; RNA sequencing, especially full-length long-read sequencing, can connect alternative exons within individual transcripts. ribosome profiling supplies evidence that candidate reading frames are translated. However, an RNA isoform is not proof of a stable protein, and none of these methods alone establishes the combination of post-translational modifications on the mature chain. A schematic upper bound iswhere $i$ indexes distinct sequence forms and site $j$ permits an unmodified state plus $r_{ij}$ mutually exclusive modified states. This assumes independence between sites and that every combination is realizable. Steric constraints, processing, mutually exclusive pathways and low occupancy invalidate that assumption in real cells. Multiplying all documented sites therefore estimates a possible space, not the number that exists.

bottom-up proteomics provides a broad experimental survey. Extract proteins under conditions that minimize proteolysis and preserve labile modifications; fractionate, digest with complementary proteases, and analyse peptides by liquid chromatography-mass spectrometry and tandem mass spectrometry. Search against a sample-specific sequence database and relevant modification hypotheses, then validate sites with diagnostic fragments and, where needed, synthetic standards. Modification-specific enrichment increases sensitivity but changes the sampled population and cannot supply an unbiased count by itself. Control peptide- and protein-level false discovery rates, distinguish unique from shared peptides, and report ambiguously localized modifications explicitly. Enlarging a search to every possible modification greatly increases the chance of a convincing but incorrect match.

The central limitation is loss of linkage. Suppose sites A and B occur on different digestion products. A mixture containing equal amounts of unmodified and doubly modified chains gives 50% modification at each site. A different mixture containing equal amounts of A-only and B-only chains gives exactly the same site occupancies, but contains different intact forms. No amount of more precise measurement of these two isolated peptides distinguishes the populations. A spanning peptide, a larger linked fragment or intact-chain evidence is required.

top-down proteomics addresses this by separating and measuring intact proteins before fragmenting their selected ions. High-resolution intact mass constrains the total composition, while sequence fragments connect modifications to the same molecule and localize them. Electron-based fragmentation can help retain modifications lost during energetic fragmentation. middle-down proteomics uses larger fragments to recover partial linkage when complete intact-chain characterization is difficult. John C. Tran and colleagues demonstrated discovery-scale intact-protein analysis, illustrating that sequence variants and modification patterns can be mapped together rather than reconstructed solely from disconnected peptides.^[ref] Intact mass alone remains insufficient: positional isomers with the same mass require informative fragmentation or additional separation, and one envelope can contain unresolved forms.

A practical programme would combine these measurements across well-defined human cell populations, using biological replicates, standardized handling and a documented range of physiological perturbations. It would use sequence-resolved RNA data to constrain searches, broad bottom-up data to locate promising variation, and targeted top-down or middle-down analysis to establish co-occurrence. Spike-in proteins spanning abundances and sizes would measure extraction loss and detection sensitivity. Time courses, immediate protein denaturation, protease and phosphatase inhibition, and processing blanks would help distinguish cellular modification from oxidation, protein deamidation or cleavage during preparation. Very large, hydrophobic and scarce proteins require specific extraction and separation strategies; their absence from a spectrum cannot be treated as biological absence.

Bulk and single-cell measurements answer different questions. A bulk sample may show two proteoforms expressed in different cells; it does not show that both occur in each cell. Conversely, detecting two modifications in one cell does not demonstrate that they occupy the same protein molecule. Single-cell sensitivity and molecular linkage must therefore be evaluated separately. Quantitative standards and targeted follow-up can establish whether a new low-abundance assignment is reproducible rather than a one-off incorrect match.

Finally, merge identifications by molecular identity rather than by peptide count, search-engine entry or ion charge. Record fully characterized forms separately from groups sharing an unresolved mass or site pattern, and control identification error at the proteoform level. Plot discovery against sampling depth, tissues and perturbations; any extrapolation to unseen forms requires explicit assumptions about abundance and sampling heterogeneity. Sequence prediction supplies candidates, peptide analysis supplies coverage, and intact or linked-fragment evidence establishes combinations. A universal exact count cannot be inferred by multiplying modification sites or summing database entries.

First establish that proteins cross the organelle boundary; then define its resident proteome and determine which residents arrive by import. A protein detected near an organelle may be a surface binder, contaminant, transient visitor or locally synthesized product. These possibilities require different controls.

Start with an operational definition of the new organelle: its location, boundary, ultrastructure and reproducible biochemical enrichment. Fluorescence microscopy with independent markers and electron microscopy can determine whether it is membrane-bounded and whether it contacts or engulfs other compartments. A condensate without a membrane can recruit proteins by partitioning; that should not be mistaken for translocation through a membrane. Purification by density-gradient centrifugation or affinity isolation should include markers for likely contaminants and measurements of organelle integrity. An enriched fraction is a starting material, not evidence of import by itself.

Choose candidate proteins from fractionation, imaging or sequence predictions and make minimally perturbing labeled versions. Follow newly synthesized protein using a pulse-chase experiment and independently verify its position relative to the organelle boundary. Loss of a cytosolic precursor followed by accumulation of an internal mature form is suggestive, but proteolytic processing alone does not demonstrate translocation. Tags can obscure targeting signals or change folding, so compare different tag positions and validate endogenous localization where possible.

The key biochemical test is an organelle import assay coupled to a protease protection assay. Incubate isolated intact organelles with a labeled precursor, then remove externally accessible protein with protease. Imported lumenal or matrix protein should be protected in intact organelles but become sensitive after detergent disruption. Surface-bound controls must remain accessible; an independent internal marker tests organelle sealing. Include organelle-free incubations to identify protease-resistant aggregates, and verify that detergent does not simply inactivate the protease. Carbonate extraction or membrane fractionation can distinguish an integral membrane product from a soluble internal one. For membrane proteins, map protected fragments and terminal accessibility rather than demanding protection of the entire chain.

Perturbation then tests the mechanism. Compare incubation time and temperature; deplete and restore relevant energy sources; dissipate a membrane potential only after confirming that this treatment preserves membrane integrity; and compete with an excess of unlabeled substrate. Energy requirements must be discovered rather than assumed. Mitochondrial matrix entry, ER translocation and peroxisomal import use different machinery. In particular, stable folding is not a universal barrier: primary peroxisome experiments demonstrated import of stably folded substrates.^[ref]

Mutating a candidate targeting signal should reduce import, while appending that signal to a suitable reporter can test sufficiency. Disrupting a candidate receptor or translocation component, followed by rescue with the wild-type protein, tests necessity. Because a blocked pathway may destroy the organelle indirectly, pair import measurements with morphology, membrane integrity and the import of unrelated controls. An import-defective allele that leaves the compartment otherwise functional is more informative than complete organelle loss. A negative isolated-organelle result does not exclude import if purification removed a required factor; compare with an intact-cell assay. Conversely, protection shows internalization but does not alone distinguish direct protein translocation from delivery inside a vesicle or engulfed compartment. Route-specific perturbations and topology measurements must resolve that distinction.

For the protein complement, combine quantitative spatial proteomics with complementary methods. Measure protein abundance across an entire fractionation gradient and identify proteins with reproducible localization profiles, rather than accepting every protein in a single pellet. Compare intact-organelle protease treatment with disrupted controls, and compare wild type with an import-defective condition. Analyze both soluble and membrane fractions. Liquid chromatography-mass spectrometry identifies peptides, but poorly soluble, scarce or unusual proteins may escape detection, so fractionation and acquisition strategies should be varied.

An internally localized TurboID or other proximity labeling enzyme can reveal proteins accessible in the relevant compartment in living cells. A cytosolic control, a catalytically inactive labeling construct and matched expression levels help identify background. Proximity labeling establishes accessibility and neighborhood, not translocation or stable residency by itself; labeling radius, reagent access and perturbation by the enzyme must be considered.^[ref]

Finally distinguish resident, imported and all imported. A resident may have been synthesized by an organelle genome; an imported protein may only transit through the compartment. Time-resolved labeling, precursor processing, localization and dependence on a defined import pathway can classify these cases. Report coverage across growth conditions, detection limits and a confidence tier for each candidate. No single proteomic experiment proves absolute completeness, but convergent topology, kinetic and genetic evidence can produce a well-supported import catalogue.

Affinity purification and proximity labeling answer related but different questions. The former enriches material that remains associated during extraction; the latter marks a neighbourhood before extraction. Neither alone proves a direct protein-protein interaction.

In affinity purification-mass spectrometry, isolate a bait protein with an antibody or an endogenous epitope tag. Lyse under conditions chosen to preserve the relevant protein complex, capture the bait on an affinity matrix, wash away background and identify co-purifying proteins by liquid chromatography-mass spectrometry after digestion into peptides. Co-immunoprecipitation is the antibody-based version of this association test. Gentle conditions preserve more weak interactions but also increase background; stringent washing improves specificity at the cost of labile partners. Extraction can disrupt membrane assemblies or create associations that were not present in intact cells.

Controls should include matched tag-only or untagged cells, an appropriate antibody control, input abundance and, where feasible, a binding-defective bait that retains its normal localization. Check that tagging has not changed the bait's abundance, localization or function. Reciprocal capture of a candidate partner is useful validation. If an association might be bridged by RNA or DNA, compare nuclease-treated and untreated samples while recognizing that nuclease treatment may dismantle a biologically genuine assembly.

For proximity labeling, fuse the bait to TurboID, which activates biotin and covalently labels accessible nearby proteins in living cells. After a timed labeling pulse, harsh lysis can be used because recovery no longer requires the original assembly to survive. Capture biotinylated material using streptavidin and identify enriched proteins by mass spectrometry. This can recover transient or insoluble neighbourhoods missed by ordinary extraction. A localization-matched control enzyme, no-added-biotin condition and matched expression help separate the bait's neighbourhood from diffuse labeling and endogenous biotinylated proteins.^[ref]

The label records proximity, accessibility and time spent nearby. A neighbour need not bind the bait; a real binder might label poorly if reactive groups are inaccessible. Pulse duration therefore trades temporal selectivity against labeling yield, rather than defining an exact universal distance cutoff.

Quantification distinguishes enrichment from a list of contaminants. Use label-free quantification of peptide signals across independent bait and control purifications, or SILAC in compatible cell cultures to compare light and heavy samples. In SILAC, isotope-containing amino acids enter newly synthesized proteins; matched peptides form distinguishable mass pairs. A label swap helps identify isotope-condition confounding. Tandem mass tags offer multiplexed comparison using reporter signals, but interfering co-isolated peptides can compress ratios.

Estimate enrichment and its reproducibility relative to matched controls, accounting for bait recovery and input abundance. Common abundant contaminants should not be promoted solely because many spectra identify them. Statistical scoring such as SAINT models the contrast between specific and background recovery across controls and replicates, allowing candidate associations to be ranked with estimated error rates.^[ref] A reproducibly enriched candidate is evidence for the assay-defined association or neighbourhood, not automatically a direct binding partner or fixed stoichiometric subunit.

Test metabolic response and verified exposure, rather than using body weight as the sole definition of efficacy. Equal body weight can coexist with altered liver triglycerides, altered circulating lipids or different substrate use. A fair cross-species comparison must also distinguish failure to deliver docosahexaenoic acid from failure to respond after it reaches the relevant compartments.

Parallel randomized interventions. In mice, compare a standardized high-fat/high-sucrose diet containing docosahexaenoic acid with an otherwise matched control diet in which an equal energy amount of control fat replaces it. Keep total fat, sugar, protein, micronutrients and energy density constant; measure actual food intake. Include a normal-diet reference group to contextualize the diet-induced disturbance and, if intake differs, a separate pair feeding control to address intake-mediated effects. The pair-fed group answers a different question from the freely fed control, so it should not replace it. Standardize age and housing, include both sexes with a planned analysis, and randomize across cages and processing batches. If diet is assigned by cage, replicate and analyze the cage-level assignment rather than treating all cage-mates as independent treatment allocations.

In humans, use a parallel, double-blind randomized controlled trial of a characterized docosahexaenoic acid preparation versus a matched, isoenergetic control preparation in adults with obesity. Choose the exposure under an approved clinical protocol, maintain background diet and activity as consistently as practical, and record medication, alcohol and other supplement use. Avoid combining one arm with an unbalanced weight-loss programme. The control oil is a defined comparator with its own possible biology, not an assumed metabolically inert substance. Block randomization on important baseline factors and blind clinical assessors and laboratory staff.

Choose dose and duration to compare achieved exposure, not simply the same milligrams per kilogram across species. Analyze the administered diets and preparations for fatty-acid composition and oxidation. Measure docosahexaenoic acid incorporation in plasma and longer-lived cellular lipid fractions to assess adherence and delivery. A predeclared study duration of roughly twelve weeks in humans, with a comparable mouse time course chosen for its biology, is an example design rather than a claim that identical calendar time implies identical metabolic exposure.

Samples and timing. Collect standardized fasting plasma before treatment and at early, intermediate and final visits, for example weeks 2, 6 and 12 in humans. In a subset, add a standardized-meal time course before and after intervention to measure postprandial trajectories rather than only a fasting endpoint. Record fasting duration, collection time, handling delay and recent diet. Collect urine for complementary small-molecule measurements. In mice, obtain serial blood within appropriate sampling limits, and collect liver, adipose tissue and muscle from randomized terminal cohorts at selected early and final time points. These terminal tissues are from different animals and must not be analyzed as within-animal repeated measurements.

Use comparable plasma fractions in both species for the primary cross-species analysis. Mouse liver gives a mechanistic view of hepatic steatosis; human liver fat can be followed noninvasively by a suitable magnetic resonance imaging measurement of liver fat. Do not require research liver biopsies solely to make the matrices match. Optional tissue collection must have separate justification. Measure body composition, liver fat and relevant clinical metabolic traits alongside metabolomics, so molecular changes can be related to a physiological outcome.

Analytical measurements. Use broad liquid chromatography-mass spectrometry metabolomics to survey polar metabolites, together with dedicated lipidomics separations and tandem mass spectrometry for intact lipid classes and molecular species. Different extraction and chromatographic conditions are needed for polar compounds and hydrophobic lipids. Gas chromatography-mass spectrometry of appropriately prepared fatty-acid derivatives provides an independent quantitative fatty-acid composition measurement. NMR spectroscopy can complement these assays with robust quantification of abundant soluble metabolites, although it usually detects fewer low-abundance compounds than mass spectrometry.

Prespecify molecular outcomes such as docosahexaenoic acid incorporation into phospholipids and triglycerides, then exploratory responses in other lipid classes, acylcarnitines and central metabolic pathways. A possible response is incorporation of more highly unsaturated lipid species without weight loss; reduced liver fat or altered postprandial handling could then reveal a metabolic effect missed by body weight. Conversely, altered precursor pools do not themselves prove increased pathway flux. Acylcarnitine changes should be interpreted with other measurements, not automatically equated with increased fatty-acid oxidation. These are hypotheses to test, not assumed treatment outcomes.

Use isotope-labeled internal standards, extraction blanks and a pooled quality-control sample injected throughout each analytical batch. Randomize sample order while balancing species, arm and time; include shared reference material across batches. Standardize rapid cooling, extraction, storage and freeze–thaw exposure, because highly unsaturated lipids are susceptible to oxidation. Verify key metabolite identities with retention behaviour, fragmentation and authentic standards where available. An accurate mass alone does not uniquely establish a lipid's double-bond positions or distinguish all structural isomers.

Statistical plan. Power the study for a limited set of primary biochemical or physiological endpoints, using anticipated variance and independent treatment units. Keep discovery lipidomics separate from confirmatory endpoints. Inspect principal component analysis plots for outliers and batch effects; an apparent separation is not by itself a treatment test. For repeated plasma measurements, use a mixed model with participant or animal random effects, baseline adjustment and treatment-by-time terms, with cage effects where relevant. Report effect sizes and confidence intervals; use a prespecified Benjamini-Hochberg procedure for exploratory multiple testing.

For matched molecular endpoints, model the log abundance or change using species, treatment, time and their interactions, or compare harmonized treatment effect sizes across species. A species-by-treatment interaction addresses differing responses. A significant result in mice and a nonsignificant result in humans does not establish that the responses differ. Differences in achieved exposure, sampled tissue, starting diet or baseline disease can still explain an apparent interaction; document these before attributing the difference to species physiology. Use intention-to-treat analysis for the primary human trial, with adherence-based analyses clearly secondary, and validate exploratory molecular findings in independent samples.

Ethics. Obtain informed consent and independent ethical review, explain uncertainty about benefit, protect identifiable molecular and clinical data, monitor adverse events and allow withdrawal. Do not induce obesity or require a harmful diet merely to mimic the mouse model, and do not withhold established care. Minimize blood and tissue sampling and justify any optional biopsy separately. Animal work likewise needs justified numbers, humane endpoints and refinement of sampling. The design should answer the cross-species question with the least invasive measurements that can distinguish exposure, molecular response and physiology.